Adaptive Biotechnologies Corporation Common Stock (ADPT) — Analysis Summary

Adaptive Biotechnologies Corporation Common Stock (ADPT) has a market cap of $2.79B with year-over-year revenue growth of +54.8%. Net margin stands at -21.5%. The stock trades at a P/E ratio of -56.2.

Key Takeaways

• Revenue changed +54.8% year-over-year
• Net margin of -21.5%
• P/E ratio of -56.2

Compared to other companies in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector, ADPT posted revenue growth of +54.8% and trades at a P/E of -56.2.